12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMG 145: Phase II data

The double-blind, international Phase II LAPLACE-TIMI 57 trial in 631 patients on a stable dose of statin therapy with or without ezetimibe showed that all doses of subcutaneous AMG 145 met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo. Specifically, AMG 145 given every 2 weeks led to mean reductions in LDL-C...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >